71 results about "Pericyte" patented technology

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to ITGB1-siRNA lipid nanoparticles and application of the ITGB1-siRNA lipid nanoparticles in anti-angiogenesis treatment. Specifically, the ITGB1-siRNA lipid nanoparticles are successfully prepared, the lipid nanoparticles are loaded with integrin beta1 small interfering RNA (ITGB1-siRNA), are modified with triptolide (TP) and are coupled with anti-Flt1 peptide, so that the lipid nanoparticles can target vascular endothelial cells (VEC) and pericytes of CNV, and a good treatment effect on the CNV is achieved. Therefore, the lipid nanoparticles researched and developed by the invention are expected to become a new choice for treating the CNV-related eye diseases, and have good practical application value.

The invention belongs to the technical field of biological medicines, and particularly relates to application of microRNA-21-3p as a target spot in preparation of a medicine for treating cerebral cavernous malformation. According to the application disclosed by the invention, it is determined for the first time that the microRNA-21-3p plays an important role in cerebral hemorrhage with cerebral cavernous malformation, the microRNA-21-3p can be used as a potential treatment target spot of the cerebral cavernous malformation, and the functions of vascular endothelial cells and pericytes can be effectively improved by improving the expression level of the microRNA-21-3p through a microRNA-21-3p agonist; therefore, a good effect of treating the cerebral cavernous malformation is achieved, and a theoretical basis is provided for researching a new target spot and a new strategy for treating the cerebral cavernous malformation.

The invention discloses a preparation method of a cochlear organ chip integrated with a blood labyrinth barrier, and belongs to the field of biomedical engineering. The preparation method of the simulated blood labyrinth barrier comprises the following steps: constructing an endothelial cell culture cavity and a pericyte culture cavity, and separating the endothelial cell culture cavity and the pericyte culture cavity through a simulated basement membrane; and respectively inoculating percutaneous cells and endothelial cells into a percutaneous cell culture cavity and an endothelial cell culture cavity, and culturing to obtain the simulated blood lost barrier. The chip can effectively simulate the structure and the function of the BLB, and the barrier integrity of the BLB is evaluated through TEER (trans-epithelial electrical resistance) measurement and an apparent permeability coefficient. The invention also relates to application of the chip in NIHL drug screening, in particular to drug evaluation for oxidative stress induced inner ear organ injury. Through the platform, the protection effect of the candidate drugs on the TBHP-induced oxidative stress injury of the inner ear organs can be evaluated, and a new tool and thought are provided for developing novel NIHL treatment drugs.

The invention discloses a medicine composition for inducing fibroblasts to be reprogrammed into pericyte-like cells (PCLCs) through a chemical small molecule combination, and the medicine composition is used for treating sepsis. According to the invention, a chemical reprogramming strategy without genetic modification is adopted, an endogenous signal channel is activated through a time sequence, and fibroblasts from somatic cells are efficiently converted into PCLCs with high expression of genes such as EMILIN3, LAMC3, GDF10, AHR, CD109, AHR, NQO1, QPRT and the like. When applied to treatment of sepsis, the medicine composition can improve pathological symptoms and reduce death rate by synergistically exerting anti-inflammatory, anti-oxidation, immune regulation and tissue barrier protection effects. The invention provides a novel safe treatment strategy based on non-genetically modified cells for sepsis.

The invention relates to the technical field of biological medicines, and discloses application of methionine adenosine transferase 2A and related substances thereof in preparation of wound repair products. According to the application disclosed by the invention, a metabolic regulation network in a diabetic wound surface is researched, so that MAT2A expression down-regulated in pericytes is found to be remarkably and negatively correlated with M1 type macrophage infiltration, and the situation that the wound healing is delayed, the wound surface blood perfusion is reduced and the inflammation macrophage infiltration is increased due to MAT2A specific deletion of the pericytes in the wound is observed; and after saMAT2A-loaded pericellular membrane coated lipid nanoparticles (PMCNPs) are further adopted for treatment, the regeneration process of the wound surface can be remarkably enhanced, continuous inflammatory macrophage infiltration in the diabetic wound surface is relieved, microcirculation recovery is promoted, the safety is high, and good application prospects are achieved in the aspect of promoting wound surface repair.

The present invention relates to an anticancer cell therapy technique targeting pericytes of tumor microenvironment by using natural killer cells in which a chimeric antigen receptor is expressed, and a technique for producing a tumor microenvironment organoid model for evaluating therapeutic efficacy, and, more specifically, provides: a pharmaceutical composition for preventing or treating cancer, comprising natural killer cells in which a CD19 chimeric antigen receptor is expressed; a glioblastoma-vascular fusion organoid prepared by co-culturing a vascular organoid and glioblastoma spheroids; a microcirculation chip on which the glioblastoma-vascular fusion organoid is mounted; and an animal model to which the glioblastoma-vascular fusion organoid is xenografted.

The present invention relates to an antibody trans-binding to a TEK receptor tyrosine kinase 2 (Tie2) of different cells, and a use thereof, and, more specifically, to: an antibody and use thereof, the antibody trans-binding to Tie2 of different cells so as to improve integrity between endothelial cells, perivascular cells, or endothelial cells and perivascular cells, thereby exhibiting preventive, ameliorative, or therapeutic effects on diseases associated with angiogenesis and increased vascular permeability, or diseases associated with decreased normal angiogenesis. The antibody trans-binding to an extracellular domain of the Tie2 protein, of the present invention, has excellent in vivo vascular protective activity and angiogenesis inhibitory activity, and the cluster of the antibody exhibits the activity of promoting angiogenesis, and thus can be very effectively used in the development of therapeutic agents for preventing, alleviating, or treating diseases associated with angiogenesis, increased vascular permeability, or decreased normal angiogenesis.

In some embodiments, devices for use as blood-brain barrier models are disclosed. The devices may include either a hydrogel component that surrounds a channel formed between a first opening and a second opening of the hydrogel component, or a hydrogel component that forms a groove. The devices may further include pericytes disposed in the channel or the groove, and endothelial cells may be disposed in the channel or the groove. The hydrogel component may include astrocytes (e.g., printed into the hydrogel component via projection stereolithography). Also disclosed are various methods of making and using these devices.

The application discloses a use of a solute carrier family 25A33 gene in preparation of a medicament for treating presbycusis, and the use is achieved by enhancing SLC25A33 expression on an endolymphatic vascular stripe, by maintaining mitochondrial function stability of pericyte cells around the vascular stripe, by reducing active oxygen free radical (ROS) generation, and by blocking TGFbeta / SMAD pathway-mediated pericyte differentiation, so as to protect the integrity of the blood labyrinth barrier. Animal experiments show that overexpression of SLC25A33 can significantly reduce the hearing threshold of a presbycusis model mouse, protect the structure of the blood labyrinth barrier, and improve the expression of tight junction proteins, and the SLC25A33 gene has the potential to treat presbycusis.

The present invention relates to an anticancer cell therapy technique targeting pericytes of tumor microenvironment by using natural killer cells in which a chimeric antigen receptor is expressed, and a technique for producing a tumor microenvironment organoid model for evaluating therapeutic efficacy, and, more specifically, provides: a pharmaceutical composition for preventing or treating cancer, comprising natural killer cells in which a CD19 chimeric antigen receptor is expressed; a glioblastoma-vascular fusion organoid prepared by co-culturing a vascular organoid and glioblastoma spheroids; a microcirculation chip on which the glioblastoma-vascular fusion organoid is mounted; and an animal model to which the glioblastoma-vascular fusion organoid is xenografted.

The present invention relates to pharmaceutical compounds and formulations comprising said compounds, wherein said compounds have the structure according to Formula I or II. The compounds and formulations are suitable for use as medicaments for the prevention or treatment of diseases or conditions characterized by percutaneous cell dysfunction, detachment and / or loss, for medical treatment for vascular stabilization, for treatment for promoting, restoring or maintaining attachment of percutaneous cells to blood vessels, and / or for the treatment of vascular-related diseases in patients. (I) (II)

The present invention relates to a composition for preventing or treating diabetic retinopathy, comprising a peptide having an excellent effect of inhibiting the generation of neovascularization in the retina, the loss of perivascular cells, and the expansion of blood vessels. The present invention can be effectively used in the prevention or treatment of retinopathy by inhibiting increase in vascular permeability, inflammation, and the occurrence of neovascularization.

The present invention provides methods of differentiating pericytes from pluripotent stem cells comprising culturing steps in chemically defined culture medium. A population of exogenously derived pericytes from PSCs are also contemplated. Further uses of the exogenously cultured pericytes for an in vitro disease model or in vitro angiogenesis assay are contemplated, including an in vitro 3D model of vasculature.

Provided is a structure composed of a cell population comprising endothelial cells, astrocytes and pericytes, and a 3D (three dimensional) cell growth material within which the cell population is located. The structure has a TEER value of at least 450 Ω / cm2. The cells of the structure may be derived from the brain. The cells may be human cells, and in particular may be primary derived non-immortalised cells. The structure is particularly suited for use in a model of the blood brain barrier, and the invention also provides such a model. The structure is located in a container, in which it separates a first chamber located on a first side of the structure and a second chamber located on a second side of the structure. The first and second chambers respectively contain first and second liquids in contact with first and second sides of the structure. The liquids mimic the brain extracellular fluid and the blood. The blood brain barrier model provided may be used in models of brain disease, and to investigate uptake of agents into the brain or diseased brain.

A multi-chimeric cell created by ex vivo fusion of three or more hematopoietic stem cells, mesenchymal stem cells, myoblasts, pericytes, or satellite cells, or a combination thereof, from three or more different donors is provided, as is the use of these cells in transplant therapy and treatment of immune deficiency and genetic disorders.

The invention discloses a pericyte targeting active peptide and application thereof in preparation of antitumor drugs, and relates to the technical field of medicines. The percutaneous cell targeting active peptide is obtained by condensation of NKX2-3 fragment peptide RVLFSQAQV, FELERRFKQQ, RYLSAPEREH, LASSLKLTST, QVKIWFQNRR or YKCKRQ and N-carbobenzoxy dipeptide (Z-Gly-Pro, Z-GP), and the fragment peptide RVLFSQAQV, FELERRFKQQ, RYLSAPEREH, LASSLKLTST, QVKIWFQNRR or YKCKRQ and N-carbobenzoxy dipeptide (Z-Gly-Pro, Z-GP) are respectively Z-GP-NB1, Z-GP-NB2, Z-GP-NB3, Z-GP-NB4 The percutaneous cell targeting active peptide can effectively block the transcriptional activity of NKX2-3, recover the contractility of tumor percutaneous cells and enhance the local vascular tension of tumors, so that the tumor distal metastasis is inhibited, and the percutaneous cell targeting active peptide is expected to be applied to the treatment of patients with malignant tumors accompanied by the distal metastasis.

The invention discloses an application of a solute carrier family 25A33 gene in preparation of a medicine for treating senile deafness, which is characterized in that SLC25A33 expression on inner ear vascular lines is enhanced, the mitochondrial function stability of vascular periripple cells is maintained, the production of reactive oxygen species (ROS) is reduced, and pericyte differentiation mediated by a TGF (Transforming Growth Factor) beta / SMAD pathway is blocked, so that the senile deafness is inhibited, and the senile deafness is inhibited. Therefore, the integrity of the blood lost barrier is protected. Animal experiments show that overexpression of the SLC25A33 can significantly reduce the hearing threshold of an age-related deafness model mouse, protect the structure of a blood labyrinth barrier and improve the expression of tight junction protein, and the SLC25A33 gene has the potential of treating age-related deafness.

The present invention relates to a microfluidic device configured to study epithelial and / or endothelial barrier function in a human 3D cell microtissue model, while simultaneously allowing for the application of mechanical stimuli such as luminal flow and / or lateral flow. Embodiments include three cultures representing the maternal-fetal interface (placental barrier): human umbilical vein endothelial cells (HUVEC), human placental fibroblasts (HPF), and human placental pericytes (HPP), as well as a ductal interface composed of human primary mammary gland-derived endothelial cells, fibroblasts, and epithelial layer (MCF10). The model is expandable to include tumors (cell line-derived or patient-derived). The present invention further relates to a method for fabricating a human 3D vascular microtissue model using a microfluidic device according to the present invention, and to the use of a human 3D vascular microtissue model for, for example, studying the effects of cell barrier function (solute permeability), interstitial flow, luminal flow and / or lateral flow, and epithelial and / or endothelial barrier function (solute permeability), and extravascular matrix properties (diffusivity, stiffness, transport of molecules, antibodies and / or cells, and matrix proteins). The present invention further relates to a method for presenting a pre-eclampsia (disease) model of the placental barrier, and means for testing drug therapies.

The present invention relates to a composition for inducing differentiation of cranial neural crest stem cells into perivascular cells, a method for producing perivascular cells from cranial neural crest stem cells, and a cell therapeutic agent composition for preventing or treating brain nervous system diseases using the perivascular cells or bone diseases using the cranial neural crest stem cells. The composition and method for inducing differentiation of cranial neural crest stem cells into perivascular cells according to an aspect of the present invention enable the specific production of from cranial neural crest stem cells. In addition, the perivascular cells can be used as a cell therapeutic agent for brain nervous system diseases and using the cranial neural crest stem cells can be used as a cell therapeutic agent for bone diseases.

The application provides a specific single biomarker NADH dehydrogenase alpha subcomplex subunit 4-L2 (NDUFA4L2) for detecting pericytes. The biomarker is located in the mitochondria of pericytes. The application also provides application of NDUFA4L2 in pericyte identification. The specific single biomarker NDUFA4L2 provided by the application has a pericyte recognition accuracy of more than 90%, which is higher than the accuracy of pericyte recognition of the previously generally considered pericyte marker, and can be used as a novel single pericyte biomarker with higher specificity.

The invention provides a smoke disease model and a construction method and application thereof, and belongs to the technical field of smoke disease model construction. The method for constructing the smog disease model comprises the following steps: extracting CD34 + hematopoietic progenitor cells in peripheral blood of a smog disease patient, reprogramming to generate hiPSC, further differentiating into brain organs and vascular organs, fusing the brain organs and the vascular organs, and culturing and constructing the vascularized brain organ smog disease model. The smoke disease model constructed by adopting the construction method disclosed by the invention can simulate and reproduce phenotypes such as tiny branch increase, macrovascularization, pericytopenia, smooth muscle fibrosis deposition, abnormal angiogenesis increase and the like in clinical core pathological phenotypes of smoke disease patients, and is superior to existing animal and cell models to a certain extent.

The method to produce conditionally apoptotic cells comprises modifying a cell population with a phenotype attributable to human adipose tissue-derived pericytes (AD-PC) expressing anti-tumor TRAIL introducing a sequence coding a conditional suicide gene (CSG).

The present disclosure is directed to methods of genetically subtyping peripheral t-cell lymphoma.

This product is an eye beauty device that stimulates the cells around the eyes with microcurrents, thereby promoting blood circulation and providing beauty benefits.

Provided is a microfluidic chip for in vitro organoid culture, comprising: a bottom region comprising a center channel and at least one side channel adjacent thereto, the bottom region further comprising a cell-laden medium within the center lane, the cell-laden medium comprising pericytes and astrocytes, and at least one side channel having therein brain microvascular endothelial cells (BMVECs) that form a lumen within the at least one side channel, an upper region; and a porous membrane arranged between the bottom region and the upper region.

To provide STAT degraders and uses thereof.SOLUTION: The present invention provides compounds, compositions thereof, and methods of using the compositions. In some embodiments, the present invention provides a method of treating a hematologic malignancy selected from LGL leukemia (T cell and NK cell), cutaneous T cell lymphoma (CTCL), peripheral T cell lymphomas (PTCL, all subtypes including ALCL), diffuse large B cell lymphoma (DLBCL), acute myelogenous leukemia, multiple myeloma, and myelofibrosis.SELECTED DRAWING: None

The invention provides a vision training essential oil composition for improving vision and preventing myopia and application thereof, and relates to the field of external essential oil. Comprising eye protection essential oil and breathing essential oil, the eye protection essential oil is prepared from the following raw materials in parts by volume: 1 to 3 parts of clary sage essential oil, 2 to 5 parts of chamomile essential oil, 1 to 3 parts of permanent flower essential oil, 1 to 3 parts of sandalwood essential oil, 2 to 5 parts of frankincense essential oil and 85 to 95 parts of coconut oil. The breathing essential oil comprises the following raw materials in parts by volume: 40-50 parts of peppermint oil, 1-3 parts of frankincense essential oil and 40-55 parts of coconut oil. By means of the essential oil composition, the activity of periorbital cells is improved, and then the effect of adjusting vision is achieved. And the eyesight of teenagers can be effectively improved by matching with massage and movement.

The invention relates to the technical field of biological medicines, and discloses application of methionine adenosine transferase 2A and related substances thereof in preparation of anti-aging products. The invention finds that methionine adenosine transferase 2A (MAT2A) can induce mitochondrial metabolism brittleness through HMGCS1-mediated ubiquinone synthesis, so that the methionine adenosine transferase 2A (MAT2A) plays an unreported metabolic part-time role in regulating cell senescence. The specific improvement of the expression quantity of the MAT2A gene in the pericyte is beneficial for improving the cell proliferation activity, the cell mitochondrial respiration level, the cell oxygen consumption rate, the cell total ATP level and the expression level of a nuclear morphological marker LamB1, and meanwhile, the senescence cell percentage and the expression level of a senescence marker P21 are reduced; related substances for improving expression of methionine adenylyltransferase 2A can be used for preparing anti-aging drugs.

The present invention relates to a pharmaceutical compound and a formulation comprising the compound, wherein the compound is of formula I or II: The present invention relates to a pharmaceutical compound and a formulation having the structure shown in JPEG2026522984000107.jpg75161. The compound and the formulation are suitable for pharmaceutical use in the prevention or treatment of diseases or disorders characterized by pericyte dysfunction, detachment and / or loss; in therapeutic treatments for vascular stabilization; in treatments for promoting, restoring or maintaining pericyte adhesion to blood vessels; and / or in the treatment of vascular-related diseases in patients.

The invention relates to the technical field of cell therapy, and particularly discloses a repairable fibroblast preparation for treating pelvic organ prolapse. The active ingredients of the preparation are fibroblasts which highly express HAS1, POLR3G and DDR2 at the same time and do not express alpha-smooth muscle actin, and the preparation is compatible with pharmaceutic adjuvants such as normal saline, human serum albumin and dimethyl sulfoxide. The dosage form of the composition comprises an injection and a gel containing a hyaluronic acid matrix. The preparation method comprises the following steps: performing enzymolysis treatment to obtain primary cells, promoting repair phenotypic differentiation through estrogen induction, purifying target cells by adopting a fluorescence labeling flow sorting technology, and performing amplification in a serum-free culture medium to prepare a final preparation. According to the preparation, through the synergistic effect of fibroblasts and pericytes and the perivascular positioning characteristic, targeted repair of pelvic floor supporting tissue can be achieved; according to the preparation method, the cell phenotype stability and the preparation reproducibility are ensured by optimizing process parameters and quality control standards.